US19249H1032 - Common Stock
COHERUS BIOSCIENCES INC
NASDAQ:CHRS (5/3/2024, 7:00:00 PM)
After market: 2.25 -0.02 (-0.88%)2.27
+0.1 (+4.61%)
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 299 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development, and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. The firm markets UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States (the U.S). The company also sells CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, in the U.S. The firm also focused on developing Humira, a biosimilar YUSIMRY (adalimumab-aqvh) in the U.S.
COHERUS BIOSCIENCES INC
C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200
Redwood City CALIFORNIA 94065
P: 16506493530
CEO: Dennis M. Lanfear
Employees: 299
Website: https://www.coherus.com/
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024...
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...
Here you can normally see the latest stock twits on CHRS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: